10:05 AM EDT, 07/16/2025 (MT Newswires) -- OKYO Pharma ( OKYO ) said Wednesday its phase 2 trial of urcosimod, formerly OK-101, showed a 'marked reduction' in neuropathic corneal pain as early as the study's fourth week, meeting the trial's primary endpoint.

Additionally, OKYO Pharma ( OKYO ) said no serious adverse events were reported among the 18 patients throughout the trial.

The bio-pharmaceutical company said it plans to meet with the US Food and Drug Administration to discuss the next steps for urcosimod, which has already received Fast Track designation for treating neuropathic corneal pain.

Price: 2.70, Change: -0.05, Percent Change: -1.82